Shares in the company rose 1 percent as investors took comfort from the manageable size of the fine and the removal of an uncertainty overhanging the stock. GSK has also struggled this year with poor sales in the United States. …
KARACHI: GlaxoSmithKline Consumer Healthcare Pakistan Limited (GSKCH) got listed at the Pakistan Stock Exchange (PSX) on Wednesday and its share price shot to the one-day maximum high limit of 5% in no time after …
Apparently waking up to its responsibility in protecting minority investors and sending a strong signal to multinationals, the Securities and Exchange Commission (SEC) may have barred GlaxoSmithKline ... from the Nigerian Stock
Research Triangle Park, N.C. — Drug giants GlaxoSmithKline (NYSE ... Pfizer Chief Executive Officer Jeff Kindler in a joint statement issued to the London Stock Exchange. "With the strength of the companies' current HIV products, as …
Glaxosmithkline, the pharmaceuticals group, is pressing the Government to force tobacconists and newsagents to stock anti-smoking products prominently alongside cigarettes. The proposal is at the heart of GSK's submission to the …
while GSK chose to get rid of the well-known brands to focus on its core pharmaceutical business. According to the Managing Director, Suntory Beverage and Food Nigeria, Mr. Chinedum Okereke, takeover procedures with the Nigerian …
Punch12mon
Nomura maintains a reduce rating on GSK Pharma and has also slashed its 12-month target ... However, the market expects strong revival in EBITDA margins and the stock is factoring in possible delisting if parent Glaxo Plc buys back …
Over the long term, shares have proven very stable. Sometimes misconstrued as an American stock because the name is so popular, GlaxoSmithKline PLC (NYSE: GSK) is actually headquartered in the United Kingdom. Dividends are …
GlaxoSmithKline is one of the five most valuable companies listed on the stock market. Breaking it up, in the way Mr Woodford is proposing, would mean the company changing radically and is likely to involve a heated conflict between …
BBC1y
Drug developer Biota Holdings Ltd has been advised that the Japanese arm of global pharmaceutical firm GlaxoSmithKline (GSK) will increase its stock of the anti-flu drug Relenza, which Biota has licensed to GSK. GSK in …